Cargando…
Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad
Seasonal influenza is a major public health problem, particularly in older people. Influenza vaccine is the most effective way to prevent influenza virus infection and its complications, but due to immunosenescence, older people do not respond efficiently to immunization. In 2009, a high-dose trival...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374036/ https://www.ncbi.nlm.nih.gov/pubmed/32515178 http://dx.doi.org/10.37201/req/043.2020 |
_version_ | 1783561612537364480 |
---|---|
author | de Miguel, Ángel Gil Marguello, Esther Redondo Domingo, Javier Díez de Lejarazu, Raúl Ortiz Torres, Federico Martinón |
author_facet | de Miguel, Ángel Gil Marguello, Esther Redondo Domingo, Javier Díez de Lejarazu, Raúl Ortiz Torres, Federico Martinón |
author_sort | de Miguel, Ángel Gil |
collection | PubMed |
description | Seasonal influenza is a major public health problem, particularly in older people. Influenza vaccine is the most effective way to prevent influenza virus infection and its complications, but due to immunosenescence, older people do not respond efficiently to immunization. In 2009, a high-dose trivalent influenza vaccine (IIV3-HD), containing four times more antigen than the standard-dose vaccine, was approved in the United States for the immunization of people aged 65 years and over. Numerous clinical trials, carried out at different seasons and using different methodologies, have shown that the IIV3-HD vaccine is, as well as safe, more immunogenic and more effective than the standard-dose vaccine in preventing influenza virus infection and its complications in older people. This paper reviews the available evidence on the efficacy and effectiveness of the IIV3-HD influenza vaccine in the elderly, with information from randomized clinical trials, as well as observational studies of real-world clinical practice and in systematic reviews/meta-analyses. |
format | Online Article Text |
id | pubmed-7374036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-73740362020-07-27 Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad de Miguel, Ángel Gil Marguello, Esther Redondo Domingo, Javier Díez de Lejarazu, Raúl Ortiz Torres, Federico Martinón Rev Esp Quimioter Revisión Seasonal influenza is a major public health problem, particularly in older people. Influenza vaccine is the most effective way to prevent influenza virus infection and its complications, but due to immunosenescence, older people do not respond efficiently to immunization. In 2009, a high-dose trivalent influenza vaccine (IIV3-HD), containing four times more antigen than the standard-dose vaccine, was approved in the United States for the immunization of people aged 65 years and over. Numerous clinical trials, carried out at different seasons and using different methodologies, have shown that the IIV3-HD vaccine is, as well as safe, more immunogenic and more effective than the standard-dose vaccine in preventing influenza virus infection and its complications in older people. This paper reviews the available evidence on the efficacy and effectiveness of the IIV3-HD influenza vaccine in the elderly, with information from randomized clinical trials, as well as observational studies of real-world clinical practice and in systematic reviews/meta-analyses. Sociedad Española de Quimioterapia 2020-06-09 2020 /pmc/articles/PMC7374036/ /pubmed/32515178 http://dx.doi.org/10.37201/req/043.2020 Text en © The Author 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Revisión de Miguel, Ángel Gil Marguello, Esther Redondo Domingo, Javier Díez de Lejarazu, Raúl Ortiz Torres, Federico Martinón Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad |
title | Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad |
title_full | Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad |
title_fullStr | Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad |
title_full_unstemmed | Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad |
title_short | Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad |
title_sort | vacuna antigripal trivalente de alta dosis. eficacia y efectividad |
topic | Revisión |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374036/ https://www.ncbi.nlm.nih.gov/pubmed/32515178 http://dx.doi.org/10.37201/req/043.2020 |
work_keys_str_mv | AT demiguelangelgil vacunaantigripaltrivalentedealtadosiseficaciayefectividad AT marguelloestherredondo vacunaantigripaltrivalentedealtadosiseficaciayefectividad AT domingojavierdiez vacunaantigripaltrivalentedealtadosiseficaciayefectividad AT delejarazuraulortiz vacunaantigripaltrivalentedealtadosiseficaciayefectividad AT torresfedericomartinon vacunaantigripaltrivalentedealtadosiseficaciayefectividad |